CFO of China’s Simcere Sees Year of Acquisitions For 2008 - PharmAsia News Spotlight
This article was originally published in PharmAsia News
Executive Summary
BEIJING - One of China's leading drug makers, Simcere Pharmaceutical Group, is set to speed up its expansion through a series of acquisitions throughout 2008
You may also be interested in...
Innovative Drug Developer Simcere Reports Falling Profits; Negotiates With Government Over Inclusion In National Insurance Catalogue
BEIJING - Simcere Pharmaceutical Group posted lower-than-expected earnings for the third quarter of 2009 as the worldwide economic slowdown and limited health insurance coverage inside China hurt sales of the outfit's most innovative and expensive biopharmaceutical, according to Simcere's leadership
Innovative Drug Developer Simcere Reports Falling Profits; Negotiates With Government Over Inclusion In National Insurance Catalogue
BEIJING - Simcere Pharmaceutical Group posted lower-than-expected earnings for the third quarter of 2009 as the worldwide economic slowdown and limited health insurance coverage inside China hurt sales of the outfit's most innovative and expensive biopharmaceutical, according to Simcere's leadership
Simcere Enters Co-development Partnership With San Francisco Biotech Outfit On Monoclonal Antibody Treatment, Scans China For Takeover Targets
BEIJING - While reporting a strong rise in earnings for 2008, the leaders of China's Simcere Pharmaceutical Group said they have signed a co-development deal with a San Francisco biotech firm on a monoclonal antibody treatment for cancer